Management changes at Seattle Genetics
This article was originally published in Scrip
Bruce Seeley has been appointed executive vice-president of commercial at Seattle Genetics (US). He has more than 18 years' experience in oncology drug marketing and sales, having most recently served as senior director for Herceptin (trastuzumab) and T-DM1 marketing at Genentech (Roche). Seattle Genetics has also promoted its general counsel Kirk Schumacher to the additional role of vice-president of legal affairs and compliance.